To evaluate the effect of romosozumab followed by alendronate on lumbar spine aBMD and TBS in postmenopausal women with osteoporosis and type 2 diabetes.
Key Findings:
Romosozumab led to significantly greater gains in LS aBMD and TBSTT at month 12 compared to alendronate (p < 0.05).
Gains from romosozumab were maintained after transitioning to alendronate and persisted significantly at months 24 and 36 (p < 0.05).
TBSTT percentage changes weakly correlated with LS aBMD percentage changes from baseline to month 36 (R2 = 0.1493).
Interpretation:
In postmenopausal women with osteoporosis and type 2 diabetes, romosozumab followed by alendronate significantly improved LS aBMD and TBSTT, indicating potential enhancement of bone strength independent of abdominal fat, which may influence treatment strategies for osteoporosis.
Limitations:
Post hoc analysis may introduce bias and limit generalizability; further studies are needed to confirm findings.
The study only included women with a history of diabetes, limiting applicability to broader populations and other demographics.
Conclusion:
Romosozumab may improve bone strength in patients with type 2 diabetes, suggesting a beneficial treatment strategy for osteoporosis in this population.
